Ethyl chloroformate → Ethyl (6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)carbamate
反応式
[CH3:1][N:2]([CH3:22])[CH:3]([CH2:20][CH3:21])[CH:4]([C:10]1[CH:19]=[CH:18][C:13]2[N:14]=[C:15]([NH2:17])[S:16][C:12]=2[CH:11]=1)[N:5]1[CH:9]=[CH:8][N:7]=[CH:6]1.CCN(C(C)C)C(C)C.Cl[C:33]([O:35][CH2:36][CH3:37])=[O:34]>C(Cl)Cl.CC(O)=O.C1COCC1>[CH3:1][N:2]([CH3:22])[CH:3]([CH2:20][CH3:21])[CH:4]([C:10]1[CH:19]=[CH:18][C:13]2[N:14]=[C:15]([NH:17][C:33](=[O:34])[O:35][CH2:36][CH3:37])[S:16][C:12]=2[CH:11]=1)[N:5]1[CH:9]=[CH:8][N:7]=[CH:6]1参加物
7
反応物 3
生成物 1
試薬・触媒・溶媒 3
実験手順
A solution of 6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-amine (52 mg, 0.16 mmol) and Hunig's base (31.6 μL, 0.18 mmol) in DCM (1 mL) was treated with ethyl chloroformate (17.3 μL, 0.0.18 mmol) in 2 mL 10% AcOH in THF. The mixture was stirred at room temperature overnight. The solution was concentrated in vacuo and the residue was purified using PTLC on a 1 mm silica plate eluting with 5% MeOH (2N NH3)/DCM to provide Ethyl (6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)carbamate. MS (ESI) m/z 388.17 [M+H]
後処理
- concentrationThe solution was concentrated in vacuo
- customthe residue was purified
- washeluting with 5% MeOH (2N NH3)/DCM
出典と根拠
- ORDレコード
- ord-152244c419944b0983fac14c4fa9eec7
- 出典データセット
- uspto-grants-2013_08
- 特許番号
- US08513291B2
反応ノート
読み込み中…